LPA
LPA encodes apolipoprotein(a), which combines with LDL to form Lipoprotein(a), a highly harmful particle in the blood. Levels of this particle are mostly determined by genetics and represent a major independent risk factor for heart disease and aortic valve calcification.
Key Takeaways
- •Lp(a) is a highly atherogenic particle that is almost entirely determined by genetics.
- •Standard lifestyle and dietary changes have little to no impact on Lp(a) levels.
- •High Lp(a) is a major cause of early heart disease and the primary cause of aortic valve stenosis.
- •Emerging gene-silencing therapies can now lower Lp(a) levels by more than 90 percent.
Basic Information
- Gene Symbol
- LPA
- Full Name
- Apolipoprotein(a)
- Also Known As
- Lp(a)AKP
- Location
- 6q26-q27
- Protein Type
- Apolipoprotein
- Protein Family
- Apolipoprotein family
Related Isoforms
Key SNPs
Strongest known genetic variant associated with high Lp(a) levels and a significantly increased risk of coronary artery disease.
Leads to an Ile4399Met substitution; associated with elevated plasma Lp(a) and early-onset myocardial infarction.
A common variant identified in genome-wide association studies that correlates with coronary heart disease severity.
Located in a regulatory region; linked to the development and progression of calcific aortic valve stenosis.
Influences the transcriptional activity of the LPA gene and helps explain variations in Lp(a) concentration.
Overview
LPA (Lipoprotein(a)) is a unique and powerful driver of cardiovascular risk. The gene produces apolipoprotein(a), a protein that attaches itself to a standard LDL particle via a disulfide bridge. This resulting particle is called Lipoprotein(a) or Lp(a). Unlike other cholesterol markers, Lp(a) levels are almost entirely determined by your genes and do not change significantly with diet or exercise. Approximately one in five people worldwide has elevated Lp(a) levels, which places them at a significantly higher risk for heart attacks, strokes, and valve disease even if their other lipid markers appear normal.
Levels of Lp(a) in the blood are nearly 90 percent determined by your genetics, specifically the structure of the LPA gene itself. Because of this, lifestyle changes like a low-fat diet or heavy exercise have almost no effect on lowering Lp(a). It remains an independent risk factor, meaning it can cause heart disease even in individuals with perfect cholesterol levels and healthy lifestyles.
Conceptual Model
A simplified mental model for the pathway:
Intentionally simplified; the risk is driven by the total number of particles (nmol/L) rather than the total mass (mg/dL).
Core Health Impacts
- • Cardiovascular risk: Powerful independent risk factor for myocardial infarction and stroke.
- • Valve stenosis: Primary genetic driver of calcific aortic valve stenosis.
- • Vascular inflammation: Carries oxidized phospholipids that trigger arterial inflammation.
- • Pro-thrombotic: Inhibits the natural breakdown of blood clots (fibrinolysis).
- • Arterial disease: Contributes to peripheral arterial disease and carotid stenosis.
- • Therapy resistance: Resistance to traditional lipid-lowering therapies like statins.
Protein Domains
KIV-2 Repeats
Variable number of loops; the number of these repeats determines the speed of hepatic secretion and blood concentration.
KIV-9 Domain
Contains the specific cysteine residue required for the covalent disulfide linkage to apolipoprotein B-100.
Protease Domain
Homologous to the protease in plasminogen but catalytically inactive; prevents the activation of clot-dissolving enzymes.
Upstream Regulators
HNF-4α Activator
The essential liver-specific transcription factor required for the basal expression of the LPA gene.
IL-6 Activator
An inflammatory cytokine that drives a significant increase in LPA expression through the promoter.
C/EBPβ Activator
A transcription factor that works alongside HNF-4α to enhance the expression of apolipoprotein(a).
Inflammation Activator
Acute and chronic inflammatory states can lead to transient and sustained elevations in systemic Lp(a) levels.
Estrogen Inhibitor
Potently lowers Lp(a) levels; the post-menopausal decline in estrogen is a primary cause of rising Lp(a) in women.
Downstream Targets
ApoB-100 Activates
The structural protein on LDL particles that covalently binds to apolipoprotein(a) to form the Lp(a) particle.
Plasminogen Inhibits
Lp(a) competitively inhibits this enzyme, preventing the breakdown of blood clots.
TGF-β Signaling Inhibits
High levels of Lp(a) disrupt this pathway in the heart, contributing to valve calcification.
Endothelial Cells Activates
Lp(a) triggers the expression of adhesion molecules like VCAM-1, promoting immune cell recruitment.
Macrophages Activates
Lp(a) is readily taken up by these cells, leading to the formation of cholesterol-rich foam cells.
Fibrin Activates
Lp(a) binds to fibrin within blood clots, further interfering with natural fibrinolysis.
Role in Aging
Because Lp(a) levels are stable from childhood, they represent a "lifetime burden" of vascular damage. High levels essentially accelerate the biological aging of the heart valves and arteries.
Valve Calcification
Lp(a) triggers the transformation of valve cells into bone-like cells, leading to "biological rust" on the heart valves.
Chronic Inflammation
By carrying oxidized phospholipids, Lp(a) contributes to the inflammaging that damages the vascular system over decades.
Vascular Stiffening
High Lp(a) accelerates the age-related stiffening of the large arteries, increasing blood pressure and heart work-load.
Menopausal Shifts
The loss of estrogen during menopause removes a key transcriptional brake on the LPA gene, increasing risk for older women.
Endothelial Decline
Lp(a) impairs the ability of the blood vessels to dilate, mimicking the endothelial dysfunction seen in advanced aging.
Lifespan Link
Centenarian studies show that individuals with naturally low Lp(a) levels are over-represented, highlighting its role as a barrier to extreme longevity.
Disorders & Diseases
Elevated Lipoprotein(a)
A condition affecting 20 percent of the population. It is defined by blood levels over 50 mg/dL (or 125 nmol/L).
Aortic Valve Stenosis
Lp(a) promotes the calcification of the aortic valve leaflets. This narrowing is progressive and often requires surgical replacement.
Peripheral Arterial Disease
The blockage of arteries in the legs. High Lp(a) is a major contributor to the plaque that causes leg pain.
Residual Inflammatory Risk
Lp(a) explains why many people have cardiovascular events even after their standard LDL is lowered to target levels.
Thrombotic Tendency
Because apo(a) mimics plasminogen, it can stabilize blood clots and prevent them from being dissolved, making events more severe.
Interventions
Supplements
One of the few supplements known to modestly lower Lp(a) levels, though clinical benefits are debated.
Often discussed in protocols to support vascular health and potentially stabilize Lp(a) interactions.
Some studies suggest that high-dose supplementation may lead to a modest reduction in systemic Lp(a) levels.
Provides antioxidant support for lipid particles and may help reduce the inflammatory potential of Lp(a).
Improve the overall lipid environment and support cardiovascular resilience, though they do not lower Lp(a) directly.
Lifestyle
Because Lp(a) is resistant to lifestyle changes, it is critical to aggressively manage blood pressure and standard LDL.
Improves endothelial function and helps mitigate the systemic risk posed by high particle counts.
Essential for keeping the "standard" LDL particle count low, reducing the number of particles available to form Lp(a).
Smoking and high Lp(a) synergistically increase the risk of myocardial infarction and stroke.
Medicines
An antisense oligonucleotide in phase 3 trials that specifically silences the LPA gene, lowering levels by over 80%.
A small interfering RNA therapy that prevents apo(a) production, achieving reductions of more than 90%.
A first-in-class oral medication that disrupts the initial binding of apolipoprotein(a) to ApoB-100.
Injectable therapies that can lower Lp(a) by 20 to 30 percent as a secondary effect to their LDL-lowering action.
Often prescribed to individuals with very high Lp(a) to counteract the pro-thrombotic and "clot-stabilizing" effects.
Lab Tests & Biomarkers
Gold Standard
Measured in nmol/L; measures the number of particles regardless of their size.
A specific laboratory method designed to be independent of isoform size variation.
Common Tests
Measured in mg/dL; measures the weight of the particles. Can be inaccurate for risk assessment.
Does not include Lp(a); however, high Lp(a) can falsely elevate LDL-C measurements.
Advanced Markers
Measures the concentration of oxidized phospholipids carried on atherogenic particles.
Determines the number of Kringle IV repeats to assess underlying genetic risk.
Hormonal Interactions
Estrogen Transcriptional Repressor
Potently lowers Lp(a) levels; the post-menopausal decline in estrogen is a primary cause of rising Lp(a).
Thyroid Hormone (T3) Metabolic Regulator
Stimulates the clearance and inhibits the synthesis of Lp(a); hypothyroidism is linked to elevated levels.
Testosterone Potent Suppressor
Generally associated with lower Lp(a) levels; testosterone deficiency can lead to a rise in particles.
Growth Hormone Indirect Activator
Growth hormone replacement therapy has been shown to paradoxically increase plasma Lp(a) concentrations.
Cortisol Inflammatory Modulator
High levels of stress hormones can increase systemic inflammation, potentially elevating Lp(a).
FSH Complex Modulator
Rising follicle-stimulating hormone levels during menopause may contribute to dyslipidemia.
Deep Dive
Network Diagrams
Lp(a) Particle & Plasminogen Homology
Kringle IV Repeat Count vs. Concentration
Biological Role: Plasminogen Mimicry and Inflammation
The primary role of the LPA gene is the production of apolipoprotein(a) in the liver. This protein has a structure that is very similar to plasminogen, which is the enzyme responsible for breaking down blood clots. Because of this similarity, Lp(a) can interfere with the normal process of clot dissolution, making it pro-thrombotic.
Additionally, Lp(a) carries oxidized phospholipids, which are highly inflammatory. These phospholipids trigger the recruitment of immune cells to the arterial wall and promote the calcification of the aortic valve. The number of Kringle IV type 2 repeats in the gene determines the size of the protein and exerts a strong inverse influence on the blood concentration of Lp(a).
Intervention Relevance: Gene Silencing and Emerging Therapies
Experts recommend that every adult should have their Lp(a) level checked at least once. It is essential to measure the molar concentration (in nmol/L) rather than the mass (in mg/dL) to account for the size variations of the protein.
New “gene-silencing” medications like pelacarsen and olpasiran are currently in phase 3 clinical trials. These drugs specifically target the LPA mRNA and can lower Lp(a) levels by more than 90 percent. PCSK9 inhibitors, while primarily used for LDL, can lower Lp(a) by approximately 20 to 30 percent. Lipoprotein apheresis remains the most effective current method to physically remove Lp(a) for individuals with very high levels and progressive heart disease.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first sequenced apo(a) and discovered its striking structural homology to plasminogen.
A seminal Mendelian randomization study providing causal evidence for the role of Lp(a) in heart disease.
Describes the molecular mechanism by which estrogen receptors repress the LPA gene promoter.
Detailed the results of the phase 2 trial for pelacarsen, showing dramatic reductions in Lp(a) levels.
The first clinical report on muvalaplin, showing that an oral drug can effectively lower Lp(a) by disrupting assembly.
Established Lp(a) as a causal risk factor for calcific aortic valve disease through large-scale genetic analysis.